Different Genetic Signatures of Small-Cell Lung Cancer Characterize Anti-GABA

Journal

Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449

Informations de publication

Date de publication:
Dec 2023
Historique:
revised: 27 07 2023
received: 24 04 2023
accepted: 24 08 2023
pubmed: 28 8 2023
medline: 28 8 2023
entrez: 28 8 2023
Statut: ppublish

Résumé

Small-cell lung cancer (SCLC) is the malignancy most frequently associated with paraneoplastic neurological syndromes (PNS) and can trigger different antibody responses against intracellular (Hu) or neuronal surface (GABA A total of 76 SCLC tumor samples were collected: 34 anti-Hu, 14 anti-GABA CNV analysis revealed that patients with anti-GABA SCLC genetic and transcriptomic features differentiate anti-GABA

Identifiants

DOI: 10.1002/ana.26784 PMID: 37638563
pubmed: 37638563
doi: 10.1002/ana.26784
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1102-1115

Subventions

Organisme : Agence Nationale de la Recherche
ID : ANR-11-LABX-0042
Organisme : Agence Nationale de la Recherche
ID : ANR-17-CONV-0002
Organisme : Agence Nationale de la Recherche
ID : ANR-18-RHUS-0012
Organisme : Institut National de la Santé et de la Recherche Médicale
ID : SIRIC LYriCAN INCa-DGOS-Inserm_12563

Informations de copyright

© 2023 American Neurological Association.

Références

Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 2021;8:e1014.
Dalmau J, Graus F. Antibody-mediated encephalitis. New England Journal of Medicine 2018;378:840-851.
Ramanathan S, Al-Diwani A, Waters P, Irani SR. The autoantibody-mediated encephalitides: from clinical observations to molecular pathogenesis. J Neurol 2019;268:1689-1707.
Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 2019;16:535-548.
van Coevorden-Hameete MH, de Bruijn MAAM, de Graaff E, et al. The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies. Brain 2019;142:1631-1643.
Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-hu antibodies: a beneficial antitumor immune response going awry. Onco Targets Ther 2013;2:e27384.
Small M, Treilleux I, Couillault C, et al. Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. Acta Neuropathol 2018;135:569-579.
Peter E, Treilleux I, Wucher V, et al. Immune and genetic signatures of breast carcinomas triggering anti-Yo-associated paraneoplastic cerebellar degeneration. Neurol Neuroimmunol Neuroinflamm 2022;9:e200015.
Sekido Y, Bader SA, Carbone DP, et al. Molecular analysis of the HuD gene encoding a paraneoplastic encephalomyelitis antigen in human lung cancer cell lines. Cancer Res 1994;54:4988-4992.
Carpentier AF, Voltz R, DesChamps T, et al. Absence of HuD gene mutations in paraneoplastic small cell lung cancer tissue. Neurology 1998;50:1919.
Ruiz-García R, Martínez-Hernández E, García-Ormaechea M, et al. Caveats and pitfalls of SOX1 autoantibody testing with a commercial line blot assay in paraneoplastic neurological investigations. Front Immunol 2019;10:769.
Vabanesi M, Pinto A-L, Vogrig A, et al. SOX1 antibody-related paraneoplastic neurological syndromes: clinical correlates and assessment of laboratory diagnostic techniques. J Neurol 2022;270:1691-1701.
O'Donovan B, Mandel-Brehm C, Vazquez SE, et al. High-resolution epitope mapping of anti-hu and anti-Yo autoimmunity by programmable phage display. Brain Commun 2020;2:fcaa059.
Gu Z. Complex heatmap visualization. iMeta 2022;1:e43.
Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 2016;32:2847-2849.
Hoffman GE, Roussos P. Dream: powerful differential expression analysis for repeated measures designs. Bioinformatics 2021;37:192-201.
Hoffman GE, Schadt EE. variancePartition: interpreting drivers of variation in complex gene expression studies. BMC Bioinformatics 2016;17:483.
Liaw A, Wiener M. Classification and Regression by random. Forest 2002;2:18-22.
Nakaya HI, Wrammert J, Lee EK, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011;12:786-795.
Yshii LM, Gebauer CM, Pignolet B, et al. CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain 2016;139:2923-2934.
Yshii L, Pignolet B, Mauré E, et al. IFN-γ is a therapeutic target in paraneoplastic cerebellar degeneration. JCI. Insight 2019;4:127001.
Barber GN. Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses. Curr Opin Immunol 2011;23:10-20.
Dorner BG, Dorner MB, Zhou X, et al. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells. Immunity 2009;31:823-833.
Oh JE, Kim MS, Ahn CH, et al. Mutational analysis of CASP10 gene in colon, breast, lung and hepatocellular carcinomas. Pathology 2010;42:73-76.
Muñiz-Castrillo S, Hedou JJ, Ambati A, et al. Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis. Brain 2021;144:2709-2721.
Zheng S, Abreu N, Levitz J, Kruse AC. Structural basis for KCTD-mediated rapid desensitization of GABAB signalling. Nature 2019;567:127-131.
Zaenker P, Gray ES, Ziman MR. Autoantibody production in cancer-the humoral immune response toward autologous antigens in cancer patients. Autoimmun Rev 2016;15:477-483.
Goodell V, Salazar LG, Urban N, et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol 2006;24:762-768.
Goodell V, Waisman J, Salazar LG, et al. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther 2008;7:449-454.
Yonezawa S, Goto M, Yamada N, et al. Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics 2008;8:3329-3341.
Hébert J, Riche B, Vogrig A, et al. Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurol Neuroimmunol Neuroinflamm 2020;7:e883.
Vogrig A, Gigli GL, Segatti S, et al. Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol 2020;267:26-35.
Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001;49:146-154.
Knudsen A, Bredholt G, Storstein A, et al. Antibodies to CRMP3-4 associated with limbic encephalitis and thymoma. Clin Exp Immunol 2007;149:16-22.

Auteurs

Alberto Vogrig (A)

French Reference Center of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
Mechanisms in integrated life sciences Institute, (MeLiS), INSERM U1314, CNRS UMR 5284, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Clinical Neurology, Santa Maria della Misericordia University Hospital, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
Department of Medicine (DAME), University of Udine, Udine, Italy.
ORCID: 0000-0002-3652-7061

Antoine Pegat (A)

Service ENMG et Pathologies Neuromusculaires, Hôpital Neurologique P. Wertheimer, Hospices Civils de Lyon, Bron, France.
Pathophysiology and Genetics of Neuron and Muscle, CNRS UMR 5261, INSERM U1315, INMG, Université Claude Bernard Lyon 1, Faculté de Médecine Lyon Est, Lyon, France.
ORCID: 0000-0003-1563-9432

Macarena Villagrán-García (M)

French Reference Center of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
Mechanisms in integrated life sciences Institute, (MeLiS), INSERM U1314, CNRS UMR 5284, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Valentin Wucher (V)

French Reference Center of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
Mechanisms in integrated life sciences Institute, (MeLiS), INSERM U1314, CNRS UMR 5284, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Valéry Attignon (V)

Cancer Genomic Platform, Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS, Centre Léon Bérard, Lyon, France.

Emilie Sohier (E)

Gilles Thomas Bioinformatics Platform, Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS, Centre Léon Bérard, Lyon, France.
Fondation Synergie Lyon Cancer, Centre Léon Bérard, Lyon, France.

Marie Brevet (M)

Department of Pathology, Lyon Est Hospital, Hospices Civils de Lyon, Bron, France.

Veronique Rogemond (V)

French Reference Center of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
Mechanisms in integrated life sciences Institute, (MeLiS), INSERM U1314, CNRS UMR 5284, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Anne-Laurie Pinto (AL)

French Reference Center of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
Mechanisms in integrated life sciences Institute, (MeLiS), INSERM U1314, CNRS UMR 5284, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Sergio Muñiz-Castrillo (S)

French Reference Center of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
Mechanisms in integrated life sciences Institute, (MeLiS), INSERM U1314, CNRS UMR 5284, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Stanford Center for Sleep Sciences and Medicine, Stanford University, Palo Alto, CA, USA.
ORCID: 0000-0001-5958-3288

Elise Peter (E)

French Reference Center of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
Mechanisms in integrated life sciences Institute, (MeLiS), INSERM U1314, CNRS UMR 5284, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
ORCID: 0000-0002-7898-8069

Melisse Robert (M)

French Reference Center of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
Mechanisms in integrated life sciences Institute, (MeLiS), INSERM U1314, CNRS UMR 5284, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Géraldine Picard (G)

French Reference Center of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
Mechanisms in integrated life sciences Institute, (MeLiS), INSERM U1314, CNRS UMR 5284, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Lucie Hopes (L)

Department of Neurology, CHRU Nancy, Nancy, France.

Dimitri Psimaras (D)

Neurology 2 Department Mazarin, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Sorbonne Université, INSERM, CNRS, Paris Brain Institute, Institut du Cerveau et de la Moelle Épinière, ICM, Paris, France.

Anthony Terra (A)

Centre de Ressources Biologiques Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.

Corinne Perrin (C)

Centre de Ressources Biologiques Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.

Dominique Cogne (D)

Plateforme de Gestion des Echantillons Biologique, Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS, Centre Léon Bérard, Lyon, France.

Severine Tabone-Eglinger (S)

Plateforme de Gestion des Echantillons Biologique, Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS, Centre Léon Bérard, Lyon, France.

Séverine Martinez (S)

Plateforme de Gestion des Echantillons Biologique, Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS, Centre Léon Bérard, Lyon, France.

Delphine Jury (D)

Plateforme de Gestion des Echantillons Biologique, Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS, Centre Léon Bérard, Lyon, France.

Julie Valantin (J)

Plateforme Anatomopathologie Recherche, Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS Centre Léon Bérard, Lyon, France.

Nicolas Gadot (N)

Plateforme Anatomopathologie Recherche, Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS Centre Léon Bérard, Lyon, France.

Jessie Auclair-Perrossier (J)

Cancer Genomic Platform, Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS, Centre Léon Bérard, Lyon, France.

Alain Viari (A)

Gilles Thomas Bioinformatics Platform, Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS, Centre Léon Bérard, Lyon, France.

Bertrand Dubois (B)

Cancer Immune Surveillance and Therapeutic Targeting Team, Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS, Centre Léon Bérard, Lyon, France.
Lyon Immunotherapy for Cancer Laboratory, Cancer Research Center of Lyon, Lyon, France.

Virginie Desestret (V)

French Reference Center of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
Mechanisms in integrated life sciences Institute, (MeLiS), INSERM U1314, CNRS UMR 5284, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Jérôme Honnorat (J)

French Reference Center of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
Mechanisms in integrated life sciences Institute, (MeLiS), INSERM U1314, CNRS UMR 5284, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
ORCID: 0000-0002-4721-5952

Classifications MeSH